# Hepatocellular Carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hepatocellular-carcinoma

> 9 upcoming FDA catalysts in hepatocellular Carcinoma: Imfinzi® (durvalumab, AZN) on November 2026 (primary completion); livmoniplimab (ABBV) on January 2027 (primary completion); livmoniplimab (ABBV) on Jan to Apr 2027 (topline data readout); durvalumab (imfinzi) immunotherapy (BSX) on June 2027 (primary completion); and 5 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 30, 2025 | [Casdozokitug primary completion](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | withdrawn | "NCT05359861 (Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Coherus Oncology, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05359861)) |
| February 23, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT05301842 (Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05301842)) |
| May 15, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | completed | "NCT03847428 (Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03847428)) |
| July 9, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Hepatocellular Carcinoma | completed | "NCT04039607 (A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04039607)) |
| Sep to Dec 2026 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557838)) |
| September 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | delayed | "NCT05557838 (Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557838)) |
| November 2026 | [Budigalimab primary completion](https://sec-api.dev/pdufa/budigalimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT05822752 (Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05822752)) |
| Nov 2026 to Feb 2027 | [Budigalimab topline data readout](https://sec-api.dev/pdufa/budigalimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT05822752 (Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05822752)) |
| Nov 2026 to Feb 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| November 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| January 2027 | [Livmoniplimab primary completion](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109272)) |
| Jan to Apr 2027 | [Livmoniplimab topline data readout](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109272)) |
| June 2027 | [Durvalumab (imfinzi) immunotherapy primary completion](https://sec-api.dev/pdufa/durvalumab-imfinzi-immunotherapy) | BSX | Hepatocellular Carcinoma | scheduled | "NCT05063565 (TheraSphere With Durvalumab and Tremelimumab for HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Boston Scientific Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05063565)) |
| Jun to Sep 2027 | [Durvalumab (imfinzi) immunotherapy topline data readout](https://sec-api.dev/pdufa/durvalumab-imfinzi-immunotherapy) | BSX | Hepatocellular Carcinoma | scheduled | "NCT05063565 (TheraSphere With Durvalumab and Tremelimumab for HCC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Boston Scientific Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05063565)) |
| September 2027 | [Casdozokitug primary completion](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | scheduled | "NCT06679985 (A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Coherus Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679985)) |
| Sep to Dec 2027 | [Casdozokitug topline data readout](https://sec-api.dev/pdufa/casdozokitug) | CHRS | Hepatocellular Carcinoma | scheduled | "NCT06679985 (A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Coherus Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06679985)) |
| Mar to Jun 2030 | [Tremelimumab topline data readout](https://sec-api.dev/pdufa/tremelimumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT06921785 (Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921785)) |
| March 2030 | [Tremelimumab primary completion](https://sec-api.dev/pdufa/tremelimumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT06921785 (Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921785)) |

## Drugs

- [Casdozokitug](https://sec-api.dev/pdufa/casdozokitug) (CHRS)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Budigalimab](https://sec-api.dev/pdufa/budigalimab) (ABBV)
- [Livmoniplimab](https://sec-api.dev/pdufa/livmoniplimab) (ABBV)
- [Durvalumab (imfinzi) immunotherapy](https://sec-api.dev/pdufa/durvalumab-imfinzi-immunotherapy) (BSX)
- [Tremelimumab](https://sec-api.dev/pdufa/tremelimumab) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hepatocellular-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hepatocellular Carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hepatocellular-carcinoma

```bibtex
@misc{secapidev_indications_hepatocellular_carcinoma_20261116,
  title        = {Hepatocellular Carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hepatocellular-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hepatocellular_carcinoma_20261116","title":"Hepatocellular Carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hepatocellular-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
